{"identifier":"/us/usc/t21/s353c","title_num":"21","num":"§ 353c.","heading":"Prereview of television advertisements","status":null,"guid":"id146f47cd-d44e-11f0-8081-e0140d9588ee","source_credit":"(June 25, 1938, ch. 675, § 503C, formerly § 503B, as added Pub. L. 110–85, title IX, § 901(d)(2), Sept. 27, 2007, 121 Stat. 939, renumbered § 503C, Pub. L. 113–54, title I, § 102(a)(1), Nov. 27, 2013, 127 Stat. 587.)","seq_in_title":151,"parent_identifier":"/us/usc/t21/ch9/schV/ptA","ancestors":[{"identifier":"/us/usc/t21","level":"title","num":"Title 21—","heading":"FOOD AND DRUGS","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch9","level":"chapter","num":"CHAPTER 9—","heading":"FEDERAL FOOD, DRUG, AND COSMETIC ACT","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch9/schV","level":"subchapter","num":"SUBCHAPTER V—","heading":"DRUGS AND DEVICES","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch9/schV/ptA","level":"part","num":"Part A—","heading":"Drugs and Devices","status":null,"is_section":false}],"xml":"<section xmlns=\"http://xml.house.gov/schemas/uslm/1.0\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dc=\"http://purl.org/dc/elements/1.1/\" xmlns:dcterms=\"http://purl.org/dc/terms/\" style=\"-uslm-lc:I80\" id=\"id7cdb1814-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c\"><num value=\"353c\">§ 353c.</num><heading> Prereview of television advertisements</heading><subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id7cdb1815-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/a\"><num value=\"a\" class=\"bold\">(a)</num><heading class=\"bold\"> In general</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">The Secretary may require the submission of any television advertisement for a drug (including any script, story board, rough, or a completed video production of the television advertisement) to the Secretary for review under this section not later than 45 days before dissemination of the television advertisement.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id7cdb1816-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/b\"><num value=\"b\" class=\"bold\">(b)</num><heading class=\"bold\"> Review</heading><chapeau style=\"-uslm-lc:I11\" class=\"indent0\">In conducting a review of a television advertisement under this section, the Secretary may make recommendations with respect to information included in the label of the drug—</chapeau><paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id7cdb1817-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/b/1\"><num value=\"1\">(1)</num><chapeau> on changes that are—</chapeau><subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"id7cdb1818-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/b/1/A\"><num value=\"A\">(A)</num><content> necessary to protect the consumer good and well-being; or</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"id7cdb1819-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/b/1/B\"><num value=\"B\">(B)</num><content> consistent with prescribing information for the product under review; and</content>\n</subparagraph>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id7cdb181a-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/b/2\"><num value=\"2\">(2)</num><content> if appropriate and if information exists, on statements for inclusion in the advertisement to address the specific efficacy of the drug as it relates to specific population groups, including elderly populations, children, and racial and ethnic minorities.</content>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id7cdb181b-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/c\"><num value=\"c\" class=\"bold\">(c)</num><heading class=\"bold\"> No authority to require changes</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">Except as provided by subsection (e), this section does not authorize the Secretary to make or direct changes in any material submitted pursuant to subsection (a).</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id7cdb181c-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/d\"><num value=\"d\" class=\"bold\">(d)</num><heading class=\"bold\"> Elderly populations, children, racially and ethnically diverse communities</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">In formulating recommendations under subsection (b), the Secretary shall take into consideration the impact of the advertised drug on elderly populations, children, and racially and ethnically diverse communities.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id7cdb181d-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/e\"><num value=\"e\" class=\"bold\">(e)</num><heading class=\"bold\"> Specific disclosures</heading><paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"id7cdb181e-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/e/1\"><num value=\"1\" class=\"bold\">(1)</num><heading class=\"bold\"> Serious risk; safety protocol</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">In conducting a review of a television advertisement under this section, if the Secretary determines that the advertisement would be false or misleading without a specific disclosure about a serious risk listed in the labeling of the drug involved, the Secretary may require inclusion of such disclosure in the advertisement.</p>\n</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"id7cdb3f2f-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/e/2\"><num value=\"2\" class=\"bold\">(2)</num><heading class=\"bold\"> Date of approval</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">In conducting a review of a television advertisement under this section, the Secretary may require the advertisement to include, for a period not to exceed 2 years from the date of the approval of the drug under <ref href=\"/us/usc/t21/s355\">section 355 of this title</ref> or <ref href=\"/us/usc/t42/s262\">section 262 of title 42</ref>, a specific disclosure of such date of approval if the Secretary determines that the advertisement would otherwise be false or misleading.</p>\n</content>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id7cdb3f30-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s353c/f\"><num value=\"f\" class=\"bold\">(f)</num><heading class=\"bold\"> Rule of construction</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">Nothing in this section may be construed as having any effect on requirements under <ref href=\"/us/usc/t21/s352/n\">section 352(n) of this title</ref> or on the authority of the Secretary under section 314.550, 314.640, 601.45, or 601.94 of title 21, Code of Federal Regulations (or successor regulations).</p>\n</content>\n</subsection>\n<sourceCredit id=\"id7cdb3f31-81bc-11eb-b838-b6993269d559\">(<ref href=\"/us/act/1938-06-25/ch675/s503C\">June 25, 1938, ch. 675, § 503C</ref>, formerly § 503B, as added <ref href=\"/us/pl/110/85/tIX/s901/d/2\">Pub. L. 110–85, title IX, § 901(d)(2)</ref>, <date date=\"2007-09-27\">Sept. 27, 2007</date>, <ref href=\"/us/stat/121/939\">121 Stat. 939</ref>, renumbered § 503C, <ref href=\"/us/pl/113/54/tI/s102/a/1\">Pub. L. 113–54, title I, § 102(a)(1)</ref>, <date date=\"2013-11-27\">Nov. 27, 2013</date>, <ref href=\"/us/stat/127/587\">127 Stat. 587</ref>.)</sourceCredit>\n<notes type=\"uscNote\" id=\"id7cdb3f32-81bc-11eb-b838-b6993269d559\">\n<note style=\"-uslm-lc:I74\" role=\"crossHeading\" topic=\"editorialNotes\" id=\"id7cdb3f33-81bc-11eb-b838-b6993269d559\"><heading class=\"centered\"><b>Editorial Notes</b></heading></note>\n<note style=\"-uslm-lc:I76\" topic=\"codification\" id=\"id7cdb3f34-81bc-11eb-b838-b6993269d559\"><heading class=\"centered smallCaps\">Codification</heading>\n<p style=\"-uslm-lc:I21\" class=\"indent0\">Section was formerly classified to <ref href=\"/us/usc/t21/s353b\">section 353b of this title</ref> prior to renumbering by <ref href=\"/us/pl/113/54\">Pub. L. 113–54</ref>.</p>\n</note>\n<note style=\"-uslm-lc:I74\" role=\"crossHeading\" topic=\"statutoryNotes\" id=\"id7cdb3f35-81bc-11eb-b838-b6993269d559\"><heading class=\"centered\"><b>Statutory Notes and Related Subsidiaries</b></heading></note>\n<note style=\"-uslm-lc:I74\" topic=\"effectiveDate\" id=\"id7cdb3f36-81bc-11eb-b838-b6993269d559\"><heading class=\"centered smallCaps\">Effective Date</heading><p style=\"-uslm-lc:I21\" class=\"indent0\">Section effective 180 days after <date date=\"2007-09-27\">Sept. 27, 2007</date>, see <ref href=\"/us/pl/110/85/s909\">section 909 of Pub. L. 110–85</ref>, set out as an Effective Date of 2007 Amendment note under <ref href=\"/us/usc/t21/s331\">section 331 of this title</ref>.</p>\n</note>\n</notes>\n</section>","provision":null,"duplicates":[],"release":{"label":"119-46","currency_date":"2025-12-02","congress":119,"law_num":46,"excluded_laws":[],"update_num":null,"seq":363,"is_partial":false,"caveat":null,"titles_affected":["21","22","29","42"],"ingested_titles":[]},"served_from":{"label":"119-46","currency_date":"2025-12-02","congress":119,"law_num":46,"excluded_laws":[],"update_num":null,"seq":363,"is_partial":false,"caveat":null,"titles_affected":["21","22","29","42"],"ingested_titles":[]},"content_first_seen":{"label":"116-314not260not283","currency_date":"2021-01-05","congress":116,"law_num":314,"excluded_laws":[260,283],"update_num":null,"seq":225,"is_partial":true,"caveat":"Current through Public Law 116-314 (01/05/2021), except 116-260, 116-283.","titles_affected":["05","05a","06","15","16","18","21","25","28","31","33","34","42","50","54"],"ingested_titles":[]},"is_exact":true,"note":null}